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Abstract
Background: The incretin-based medicines GLP1 analogues (GLP1a) and dipeptidyl peptidase-4 inhibitors (DPP4i)
are hypoglycaemic agents licensed for the treatment of type 2 diabetes mellitus (T2DM). Although these drugs
possess comparable efficacy and low risk of hypoglycaemia, differences in terms of route of administration
(subcutaneous versus oral), effect on body weight and gastrointestinal tolerabily can impact their actual use in
clinical practice. This study aimed to describe the real-world utilization of incretin-based medicines in the Italian
clinical practice.
Methods: A multi-database, population-based, descriptive, cohort study was performed using administrative data
collected between 2008 and 2014 from three Italian geographic areas. Subjects aged ≥18 were selected. New users
were defined as those with ≥1 dispensing of GLP1a or DPP4i during the year of interest and none in the past.
Trends of cumulative annual incidence of use in the general adult population were observed. New users of GLP1a
or DPP4i were respectively described in terms of demographic characteristics and use of antidiabetic drugs during
1 year before and after the first incretin dispensing.
Results: The overall study population included 4,943,952 subjects. A total of 7357 new users of GLP1a and 41,907 of
DPP4i were identified during the study period. Incidence of use increased between 2008 (0.2‰ for both GLP1a and
DPP4i) and 2011 (GLP1a = 0.6‰; DPP4i = 2.5‰) and slightly decreased thereafter. In 2014, 61% of new GLP1a users
received once-daily liraglutide while 52% of new DPP4i users received metformin/DPP4i in fixed-dose. The percentage
of new DPP4i users older than 65 years of age increased from 30.9 to 62.6% during the study period. Around 12% of
new users had not received any antidiabetic before starting an incretin.
Conclusions: During the study period, DPP4i rapidly became the most prescribed incretin-based medicine, particularly
among older new user. The choice of the specific incretin-based medicine at first prescription appeared to be directed
towards those with higher convenience of use (e.g. oral DPP4i rather than subcutaneous GLP1a, once-daily liraglutide
rather than twice-daily exenatide). The non-negligibile use of incretin-based medicines as first-line pharmacotherapy for
T2DM warrants further effectiveness and safety evaluations to better define their place in therapy.
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Background
Incretin-based medicines are a class of hypoglycemic
agents indicated for the treatment of type 2 diabetes
(T2DM) [1]. Results from clinical trials have suggested a
positive risk/benefit balance for these medicines, with an
hypoglycemic effect comparable to other non-insulin
antidiabetic drugs (AD) and no negative effects on body
weight and risk of hypoglycemia [1, 2]. The clinical effi-
cacy of these drugs relies on the enhancement of the activ-
ity of the Glucagon-like peptide 1 (GLP1), an endogenous
peptides belonging to the family of incretin hormones that
exerts an important role in the glycemic homeostasis [1].
On the basis of the mechanism of action, currently avail-
able incretin-based medicines are distinguished in two
main groups: GLP1 analogues (GLP1a) and dipeptidyl
peptidase-4 inhibitors (DPP4i) [1, 3]. GLP1a are GLP1-re-
ceptor agonists with longer half-life compared to the nat-
urally occurring GLP1 hormone. DPP4i, instead, can
enhance the activity of the endogenous GLP1 by inhibiting
its enzymatic degradation.
The mechanism of action is not the only difference
between these two groups of hypoglicemic drugs. In
particular, GLP1a and DPP4i respectively possess fea-
tures that can differentially influence their use in clinical
practice [3, 4]. For instance, GLP1a are administered
subcutaneously while DPP4i are taken orally. GLP1a use
can cause weight loss while DPP4i have a neutral effect.
Moreover, GLP1a are generally less tolerated at gastro-
intestinal level than DPP4i, causing vomiting, nausea
and diarrhoea.
Although these medicines have been marketed over a
decade ago, little is currently known on the actual utilization
of GLP1a and DPP4i in clinical practice [5–9].
n February 2008 the first incretin-based medicines (i.e.
exenatide, vildagliptin and sitagliptin) received market-
ing authorization in Italy [5]. Since then, all licensed
medicines belonging to this drug class have been reim-
bursed by the Italian National Health Service (NHS) as
second/third line treatment for T2DM in patients with
secondary failure of prior antidiabetic treatment [5, 10].
To date, only one published study provided detailed
information on the utilization of these drugs in the
Italian clinical practice. This study was based on the
analysis of the data collected in the Monitoring Regis-
try of the Italian Medicines Agency (AIFA) between
February 2008 and August 2010 [5]. Nevertheless, due
to the limited observation period, only the first three
active substances available in Italy were included.
Moreover, no information was provided on possible
changes of utilization patterns and prescribing behav-
iours over time.
Indeed, for newly marketed drug classes, the number
of exposed patients, as well as the characteristics of
newly treated patients and the preferences of patients
and prescribers with respect to specific active substances
and formulations, are expected to change rapidly during
the period following the introduction into clinical prac-
tice [11, 12]. In this context, evidence on the real-world
utilization of medicines is paramount to understand the
magnitude of possible drug-related issues, identify early
signals of irrational drug use, and discuss measures and
interventions to improve prescribing habits [13].
Therefore, the aim of this study was to describe the
real-world patterns and trends of utilization of GLP1a
and DDP4i through the analysis of routinely collected
administrative data from three Italian geographic areas.
Methods
Data source
Italy has a tax-based, universal coverage NHS organised
in three levels: national, regional, and local. Healthcare
is managed to all the inhabitants by the Local Health
Authority (LHA) where he/she has her regular address.
This study was based on the analysis of the adminis-
trative databases from two Italian regions in central Italy,
Tuscany and Umbria, and one LHA in Southern Italy,
corresponding to the province of Caserta. The three da-
tabases collect patient-leve information on the utilization
of healthcare services in charge to the NHS and dis-
pensed to all subjects who are registered with a general
practitioner in the corresponding geographic areas. For
each subject in the database, demographic information
can be linked to all records of reimbursed drug dispens-
ings for outpatient use. Records include information on
the dispensed medicine (active substance, Anatomical
Therapeutic Chemical-ATC code, brand name, formula-
tion) as well as the date of dispensing and the number of
dispensed packages.
Study design and population
This was a multi-data base, population-based, descrip-
tive, cohort study. Data from January 1, 2008 to Decem-
ber 31, 2014 were drawn from the databases of Tuscany
and Caserta. As for Umbria, data were only available
from January 1, 2011 up to December 31, 2014. For each
year of observation, the reference study population cor-
responded to all subjects active into the databases at
January the 1st. At the same date, subjects had to be ≥18
years old and have ≥365 days of look-back. Within such
population, all subjects with ≥1 dispensing of any AD
were identified (ATC code A10* - see Additional file 1:
Appendix 1).
Trends of prevalence and cumulative incidence of use
Users of GLP1a and DPP4i were respectively identified
in each year of the study period and the annual preva-
lence and cumulative incidence of use were calculated.
Prevalent users were subjects with ≥1 dispensing of
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interest during the year of reference. New users were pa-
tients with ≥1 dispensing of interest during the year of
reference and none in the past. The annual prevalence
of use was computed as the proportion of prevalent
users in the reference population for that year. The cu-
mulative annual incidence of use was computed dividing
the number of new users in that year by the number of
subjects at risk of receiving the drug of interest in the
reference population (i.e. the reference population for
that year minus prevalent users of the previous year). In
addition, prevalence and incidence of use was also ob-
served among AD users (i.e. ≥1 dispensing of AD). To
eliminate the influence of age and sex differences across
calendar years and between geographic areas, estimates
of prevalence and incidence of use were standardized by
age and sex using the 2012 overall study population as
the reference.
Characterization of new users
Per each year of the study period, new users of a GLP1a
and DPP4i were respectively classified according to the
specific active substance they started with. Moreover,
newly treated patients with GLP1a and DPP4i were
respectively described in terms of sex, age and AD
utilization during one year before and after the first dis-
pensing of interest (index dispensing). Prior utilization
of AD was described according to the following mutually
exclusive categories (see Additional file 2: Appendix 2
for the entire list of ATC codes):
1) no AD treatment;
2) insulin use, with or without non-insulin AD,
3) non-insulin AD monotherapy,
4) ≥1 non-insulin AD pharmacotherapy.
AD utilization during the year following the index dis-
pensing was observed in patients with one complete year
of follow-up (e.g. patient that died during the first 365
day of treatment were excluded from this analysis) and
described according to the following non-mutually ex-
clusive categories:
1) ≥1 additional dispensing of the index incretin (i.e.
GLP1a or DPP4i),
2) ≥1 dispensing of a non-index incretin (i.e. switchers
from GLP1a to DPP4i and vice versa),
3) ≥1 additional dispensing of non-incretin AD,
4) ≥1 additional dispensing of any AD,
5) Persistent use of incretins (any).
As for the latter category, patients were classified as
persistent to incretin-based therapy if no treatment dis-
continuation was observed. Treatment discontinuation
was defined as a gap >90 days between the end of the
duration of a dispensing of any incretin-based medicines
and the subsequent dispensing (no stockpiling was
allowed) [14]. The duration of each dispensing was cal-
culated dividing the total amount of active substance
dispensed by the relevant Defined Daily Dose (DDD),
which is assumed to represent the average maintenance
dose per day for a drug used for its main indication in
adults (https://www.whocc.no/atc_ddd_index/).
As additional analyses, characteristics of new users
were further investigated within the subgroups of pa-
tients with no previous AD treatment.
Data management and processing
Data management was performed using a distributed
network approach. The infrastructure developed in the
Italian national project MATRICE [15] was exploited:
data from the databases of the participant institutions
were exported to a common data model and managed
locally using the open source software TheMatrix
(http://thematrix.isti.cnr.it/). The data processing proce-
dures is available as a Additional file 3. The resulting
analytical datasets were checked by study partners and
subsequently shared within the research group. All the
analyses presented in this study were performed cen-
trally at the Agenzia regionale di sanità della Toscana by
using the statistical software STATA version 12.1. The
data analysis procedure is available as a Additional file 3.
The use of data for the purposes of this study was
approved by the relevant governance boards of each
local partner.
Results
A total of 4,943,952 adult individuals from the three
geographic areas considered were included in the
study. The average number of subjects per year of
observation corresponded to around 4.5 million inhabi-
tants (Table 1): 3.2 million from Tuscany, 750,000 from
Caserta and 700,000 from Umbria (Additional file 4:
Table S1).
Overall, 7357 users of GLP1a and 41,907 users of
DPP4i were identified during the study period. The
prevalence of use of incretin-based medicines (Fig. 1a)
increased up to 2013 (1.1‰ for GLP1a and 6.1‰ for
DPP4i) and remained stable in 2014. The incidence of
use in the total study population (Fig. 1b) increased be-
tween 2008 and 2011 from 0.2‰ for both GLP1a and
DPP4i to 0.6‰ for GLP1a and 2.5‰ for DPP4i, and
then decreased until the end of the study period (0.3‰
for GLP1a and 1.4‰ for DPP4i). Similar trends were
observed when prevalence and incidence of use were
estimated among AD users (Additional file 5 Figure S1
and Additional file 6 Figure S2). In particular, both in
2013 and 2014 prevalent users of GLP1a and DPP4i re-
spectively accounted for 2 and 10% of this population.
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Both prevalence and incidence of use stratified by sex
and age bands revealed an increasingly higher
utilization of DPP4i, compared to GLP1a, in male pa-
tients with ≥65 years of age during the study period
(Additional file 7: Figure S3 and Additional file 8: Fig-
ure S4).
All new user of GLP1a in 2008 and 2009 received exe-
natide as the first prescription (Fig. 2a, data also
available in Additional file 11: Table S2a). Between 2010
and 2013 new users starting with liraglutide increased
from 38.5 to 87%. In 2014, 17% of new users received
lixisenatide and 22% exenatide. As for first drug of
choice among DDP4i (Fig. 2, panel b, data also available
in table in Additional file 11: Table S2b), in 2008, 64% of
patients started with sitagliptin and 36% vildagliptin.
From 2009 to 2014 around 50% of all new user of a
DPP4i-based therapy started a fixed-dose combination
with DPP4i/metformin.
New users of GLP1a (Table 2) had a mean age of
58.1 while those starting a DPP4i (Table 3) had a
mean age of 64.3. Those who received more than one
non-insulin AD during the 365 days before starting
incretins decreased from 58.9% in 2008 to 26.8% in
2014 for GLP1a and from 55.5 to 38.2% for DPP4i. In
the whole study period, around 12% percent of new
users of both GLP1a and DPP4i received no AD
within 365 days preceding the index dispensing. Over
the half of patients with an entire year of follow-up,
corresponding to about 85% of the whole new user
population, were persistent during the first year of
incretin-based therapy (GLP1a = 60.6%; DPP4i =
62.4%), with a very low percentage of switchers from
one to the other group (GLP1a = 5.6%; DPP4i = 1.9%).
The additional analysis of new users with no AD
dispensing during the year before the index dispens-
ing revealed that about one out of two of these pa-
tients did not receive any other AD in the 365 days
following the index dispensing and around one third
were persistent incretin users.
Overall, similar trends of utilization were observed in
the three geographic areas considered during the study
period (Additional file 9: Figure S5 and Additional file
10: Figure S6). However, in Caserta the observed age
and sex standardized incidence and prevalence of use
were higher than those observed in Tuscany and Um-
bria, both in the whole adult population and among pa-
tients treated with any AD.
Table 1 Description of the total study population
2008 2009 2010 2011 2012 2013 2014
Subjects per year, n 3 309 447 3 444 950 3 601 468 4 506 287 4 631 043 4 705 226 4 797 459
Women, % 52.5 52.6 52.6 52.7 52.7 52.7 52.7
Subjects per age band, %
18-44 44.8 44.0 43.1 41.6 40.8 39.8 38.9
45-64 33.0 33.0 33.2 33.3 33.3 33.3 33.3
65-84 20.7 21.1 21.3 22.0 22.4 22.9 23.2
85+ 1.6 2.0 2.4 3.1 3.6 4.0 4.5
Antidiabetic usersa (crude), % 5.2 5.5 5.8 6.2 6.2 6.4 6.5
Antidiabetic usersa (age-sex standardized), % 5.6 5.8 6.1 6.3 6.2 6.2 6.2
a At least one dispensing of any antidiabetic drug (ATC A10*)
Fig. 1 Age-sex standardized prevalence (a) and incidence (b) of use
of incretin-based medicines
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Discussion
Through the analysis of routinely collected administra-
tive data, this study provided evidence on the real-world
utilization of incretin-based medicines in three Italian
geographic areas, during a time span that covered the
first 7 years since the introduction of these drugs into
the Italian clinical practice.
Results from the present analysis showed a steady in-
crease of the prevalence of use of GLP1a and DPP4i be-
tween 2008 and 2013, with a plateau in 2014. A similar
figure, was reported for DPP4i in a nationwide drug
utilization study performed within the whole Danish gen-
eral population (i.e. no age restrictions were applied) [9].
Christensen and colleagues also reported a prevalence of
use of GLP1a in 2014 that was three-fold higher than that
observed in the present analysis for the same study year
(3.5‰ vs. 1.1‰), although underlying differences between
this and the study from Christensen et al. hamper direct
comparisons (e.g. different population characteristics and
standardization method, healthcare service and drug reim-
bursement policies).
As for the cumulative incidence of use, we observed a
rapid increase up to 2011, with a trend of decrease there-
after. Other than the increasingly stringent control of the
drug expenditure at national level, a possible saturation of
the target population might explain such a trend, meaning
Fig. 2 Percentage of new users of glucagon-like peptide-1 analogues (a) and dipeptidyl peptidase-4 inhibitors (b) by active
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that most of patients eligible to an incretin-based ther-
apy already started the treatment during the first 4
years of utilization.
Overall, the temporal trends of prevalence and inci-
dence of use clearly showed that DPP4i soon became
the most widely used incretin-based therapy in our
study population. In 2014, in fact, new DPP4i users out-
numbered new GLP1a users almost 9 to one. Indeed,
DPP4i allow for a less burdensome management of the
disease compared to GLP1a, given the less invasive oral
administration and the availability of fixed dose com-
bination with metformin [16].
The choice of specific active substances and formula-
tions at first prescription of a GLP1a or a DPP4i
changed considerably over time and appeared to be
directed towards newer medicines with a higher con-
venience of use. As also reported by another Danish
drug utilization study [7], we observed that, during the
study period, liraglutide [17] (administered once daily)
almost entirely replaced exenatide [18] (administered
twice daily) as the first choice for patients starting a
GLP1a-based therapy (once weekly exenatide was not
available in Italy during the study period). Similarly,
among new users of any DPP4i-containing formulation,
since 2009, when fixed dose combination with metfor-
min became available in Italy, one out of two patients
started the treatment with a formulation containing
DPP4i + metformin.
The characterization of new users of incretin-based
medicines showed that DPP4i treatment was increasingly
started in patients ≥65 years old. Probably, the more con-
venient disease management associated with the use of
these drugs compared to GLP1a becomes even more im-
portant for the treatment choice in the elderly. We also
observed that the percentage of new users of incretin-
based medicines who had already received at least two
different non-insulin AD in the previous year decreased
progressively during the study period, while those who
were already on non-insulin AD monotherapy increased.
This trend became particularly clear in both groups of
new users starting from 2011. Such changes in prescribing
behaviours are likely to be a consequence of the first re-
port from the AIFA Monitoring Registry [5] on the use of
incretin-based medicines in clinical practice, which was
made public by the Italian Medicine Agency in January
2011. Results from the report identified baseline glycated
haemoglobin as an independent predictor for effectiveness
of incretin-based therapies, as also found in other observa-
tional studies [5, 19, 20]. Therefore, our findings are likely
to reflect a tendency of prescribers to start incretins in
subjects at an earlier disease stage and/or with a better
baseline glycemic control.
Table 2 Characteristics of new users of glucagon-like peptide-1 analogues
All Data Sources 2008 2009 2010 2011 2012 2013 2014 Total
N 587 753 1 158 2 035 1 160 950 714 7 357
Women, % 55.2 52.7 51.5 49.3 50.3 46.5 46.2 50.0
Mean age 57.9 58.2 58.7 58.0 57.6 58.6 57.2 58.1
Age bands, % 18-44 8.5 9.2 8.4 10.9 10.9 11.7 12.9 10.4
45-64 65.6 63.7 63.5 62.4 63.9 57.2 61.1 62.4
65-84 25.9 26.8 28.0 26.1 24.8 29.3 25.9 26.7
85+ 0.3 0.2 0.6 0.3 1.9 0.1 0.5
Prior antidiabetic treatmentsa, % No antidiabetics 3.7 4.8 6.6 16.5 11.6 18.6 16.9 12.3
Insulin with/without non-insulin antidiabetics 23.0 25.4 22.3 20.6 25.7 23.5 19.0 22.6
Non-insulin antidiabetic monotherapy 14.3 16.3 19.9 28.2 30.0 32.4 37.3 26.3
≥1 non-insulin antidiabetic 58.9 53.5 51.2 34.7 32.7 25.5 26.8 38.9
Patients with 1 year follow-up, % 99.8 99.7 99.9 99.7 99.3 98.9 0.0 89.9
Patients with 1 year follow-up, N 586 751 1 157 2 029 1 152 939 - 6 614
Following antidiabetic treatmentsb, % ≥1 additional dispensing of a GLP1a 84.0 84.0 82.2 82.7 82.1 74.8 - 81.6
Persistent users of incretins (any) 54.3 60.6 60.1 65.1 62.2 53.3 - 60.6
Switchers to a DPP4i 3.4 3.7 6.2 5.7 8.1 4.7 - 5.6
≥1 additional dispensing of non-incretin antidiabetic 91.6 91.1 86.3 86.1 84.7 79.9 - 86.1
≥1 additional dispensing of any antidiabetic 97.1 96.7 94.5 93.2 93.1 88.2 - 93.5
GLP1a glucagon-like peptide-1 analogues, DPP4i dipeptidyl peptidase-4 inhibitors
a≥1 dispensing within 365 days preceding the index GLP1a dispensing
bDugs dispensed during 365 days following the index GLP1a dispensing were considered
Persistent use: no gaps ≥90 days between the end of the duration of a dispensing and the following one
Switchers: ≥1 dispensing of a DPP4i
Roberto et al. BMC Endocrine Disorders           (2019) 19:18 Page 6 of 9
The percentage of patients classified as persistent dur-
ing the first year of treatment was similar in DPP4i and
GLP1a users (about 60%, respectively) while the percent-
ages of switchers from GLP1a to DPP4i and vice versa
were negligible. Comparable levels of persistence were
reported in literature for GLP1a and DPP4i, respectively
[21, 22]. Moreover, the observed level of persistence was
in line with the highest figures reported for other non-
insulin ADs [23–25].
In order to promote the appropriate use incretin-based
medicines, the Italian NHS allows the reimbursement of
these medicines for a subset of the licensed indications
only. In particular, these hypoglycemic agents can be reim-
bursed as second/third line treatment for T2DM when
failure of previous oral hypoglycaemic pharmacotherapies
is reported by prescribers [10]. In contrast with such
reimbursement policy, we found that more than one in
ten new users, both in the DPP4i and GLP1a group, did
not receive any AD during the year preceding the first
incretin prescription. Notably, while DPP4i are also li-
censed as a first-line treatment for T2DM in monother-
apy, GLP1a are not even approved for such indication. In
some cases, it is possible that generic metformin was
bought without claiming reimbursement to the NHS and,
thus, its dispensing was not recorded in the administrative
databases. However, this is unlikely to completely explain
such findings since the percentage of new incretin users
without any prior dispensing of antidiabetic drug was
quite stable across time, while price of copayment in-
creased only in more recent years (http://www.regione.-
toscana.it/-/ticket-sui-farmaci). Moreover, the additional
analyses performed within this subgroup revealed a very
low level of persistence, with almost half of the patients
that did not receive any other AD during the year follow-
ing the first incretin prescription. Such patterns of use
might be, in some cases, explained by a possible attempt
to inappropriately treat prediabetes or induce weight loss
[3], two conditions for which incretin-based medicines
were not even approved for during the study period.This
study has several strengths. First, to our knowledge this is
the first, large scale, multi-database, population based
study providing an overview of the utilization of GLP1a
and DPP4i in the Italian clinical practice.
Second, we analyzed data from three Italian adminis-
trative databases which have been extensively used for
drug utilization research studies, particularly in the con-
test of diabetes [6, 8, 26, 27]. Third, the study population
was drawn from a source population of almost 5 million
Table 3 Characteristics of new users of dipeptidyl peptidase-4 inhibitors
All Data Sources 2008 2009 2010 2011 2012 2013 2014 Total
N 627 1
732
3
838
10
546
9
800
9
231
6
133
41
907
Women, % 46.1 45.6 46.8 46.6 45.4 47.0 44.1 46.0
Mean age 59.2 61.5 62.0 62.6 64.5 65.9 67.4 64.3
Age bands, % 18-44 8.3 5.6 6.3 5.7 4.5 5.1 3.3 5.0
45-64 60.8 53.8 51.2 50.2 43.6 36.8 34.2 43.8
65-84 30.6 39.8 41.7 42.8 49.6 53.8 57.5 48.5
85+ 0.3 0.8 0.9 1.3 2.4 4.2 5.1 2.7
Prior antidiabetic treatmentsa, % No antidiabetics 4.6 4.8 10.3 15.7 9.9 16.0 9.6 12.4
Insulin with/without non-insulin antidiabetics 4.9 6.9 11.5 16.7 22.0 22.2 16.1 18.0
Non-insulin antidiabetic monotherapy 34.9 30.9 26.1 27.4 29.9 28.6 36.1 29.7
≥1 non-insulin antidiabetic 55.5 57.3 52.2 40.2 38.2 33.1 38.2 39.9
Patients with 1 year follow-up (%) 99.5 99.7 99.4 99.6 99.3 98.2 0.0 84.6
Patients with 1 year follow-up, N 624 1
727
3
815
10
504
9
731
9
067
- 35
468
Following antidiabetic treatmentsb,
%
≥1 additional dispensing of a DPP4i 87.3 89.8 84.8 86.6 88.4 80.6 - 85.5
Persistent use of incretins (any) 57.2 65.5 59.1 66.7 65.3 55.4 - 62.4
Switcher to a GLP1a 2.9 2.5 3.5 2.3 1.6 0.8 - 1.9
≥1 additional dispensing of non-incretin
antidiabetic
92.5 81.5 74.8 76.7 76.0 72.6 - 75.8
≥1 additional dispensing of any antidiabetic 97.0 97.3 93.0 93.4 95.3 89.9 - 93.2
GLP1a glucagon-like peptide-1 analogues, DPP4i dipeptidyl peptidase-4 inhibitors
a≥1 dispensing within 365 days preceding the index DPP4i dispensing
bDugs dispensed during 365 days following the index DPP4i dispensing were considered
Persistent use: no gaps ≥90 days between the end of the duration of a dispensing and the following one
Switchers: ≥1 dispensing of a GLP1a
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people [28] which allowed identifying and describing a
very large number of incretin users. Fourth, we used a
distributed network infrastructure [15], which granted
consistency in the data management process across the
participant units as well as compliance with privacy
regulations. This study has also limitations. Although
data were collected from three different Italian areas,
generalizability of the results to the whole national terri-
tory cannot be assumed since drug utilization in Italy
can vary significantly at regional and local level [29].
Second, the actual dose administered to patients is not
recorded in Italian administrative data so that we used
the DDD to estimate treatment duration. The DDD, in
fact, is generally accepted as a reasonable approximation
when drug utilization studies are performed in large
populations of adult subjects on administrative data-
bases. Another limitation regards the characterization of
new users and is related to the administrative nature of
the data source used for this study. In fact, some clinical
characteristics that can influence the treatment choice in
patients with T2DM are either not recorded (e.g. body
mass index and glycated haemoglobin) or inaccurately
identified (e.g. renal and liver disease) into Italian ad-
ministrative databases.
Conclusions
A rapid increase of the incidence of use of incretin-
based medicines was observed during the first 4 years
from the introduction into the Italian clinical practice.
DPP4i soon became the most widely used incretin-based
medicines, particularly for the elderly. The choice of
specific active substances and formulations at first pre-
scription varied over time towards newer medicines with
a higher convenience of use, such as once daily liraglu-
tide for GLP1a and fixed-dose formulations containing
DPP4i/metformin. In line with current evidence and rec-
ommendations [5, 19, 20], our findings suggest that, dur-
ing the study period, incretin-based medicines were
increasingly started in patients at an earlier disease stage
and/or with a better glycemic control. GLP1a and DPP4i
users had a comparable level of persistence during the
first year of treatment, while switching from GLP1a to
DPP4i or vice versa was negligible. Finally, we docu-
mented the use of incretin-based medicines as first-line
pharmacotherapy for type 2 diabetes in more than one
out of ten new users. On the one hand, such prescribing
pattern was in contrast with national reimbursement cri-
teria and might potentially hide inappropriate utilization
behaviours. On the other hand, the execution of large
scale observational studies is warranted to evaluate the
safety and effectiveness of incretin-based medicines as
first-line pharmacotherapy for T2DM and better define
the place in therapy of these hypoglycemic agents.
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